Victory Capital Management Inc. Grows Position in Pediatrix Medical Group, Inc. $MD

Victory Capital Management Inc. increased its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 30.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,126,207 shares of the company’s stock after purchasing an additional 968,553 shares during the period. Victory Capital Management Inc.’s holdings in Pediatrix Medical Group were worth $69,114,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Pediatrix Medical Group during the third quarter worth about $513,000. Dana Investment Advisors Inc. lifted its holdings in Pediatrix Medical Group by 5.6% in the 3rd quarter. Dana Investment Advisors Inc. now owns 801,462 shares of the company’s stock worth $13,424,000 after purchasing an additional 42,162 shares in the last quarter. Hsbc Holdings PLC boosted its stake in Pediatrix Medical Group by 226.6% in the 2nd quarter. Hsbc Holdings PLC now owns 111,997 shares of the company’s stock worth $1,591,000 after purchasing an additional 77,704 shares during the period. Allianz Asset Management GmbH grew its holdings in Pediatrix Medical Group by 158.5% during the 3rd quarter. Allianz Asset Management GmbH now owns 158,777 shares of the company’s stock valued at $2,660,000 after buying an additional 97,365 shares in the last quarter. Finally, Edgestream Partners L.P. bought a new stake in shares of Pediatrix Medical Group during the second quarter valued at approximately $763,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, CEO Mark S. Ordan sold 23,000 shares of Pediatrix Medical Group stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $22.41, for a total transaction of $515,430.00. Following the completion of the sale, the chief executive officer owned 302,805 shares of the company’s stock, valued at approximately $6,785,860.05. The trade was a 7.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Zacks Research downgraded Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 23rd. UBS Group reduced their price objective on Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 24th. Truist Financial decreased their price objective on Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday, February 19th. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. Finally, Deutsche Bank Aktiengesellschaft set a $19.00 price target on shares of Pediatrix Medical Group in a research note on Friday, February 20th. One investment analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $19.80.

Pediatrix Medical Group Trading Down 3.0%

NYSE:MD opened at $19.29 on Friday. The firm has a 50-day simple moving average of $21.16 and a 200-day simple moving average of $19.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.66 and a current ratio of 1.66. The firm has a market cap of $1.60 billion, a P/E ratio of 9.94 and a beta of 0.79. Pediatrix Medical Group, Inc. has a one year low of $11.84 and a one year high of $24.99.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Thursday, February 19th. The company reported $0.50 earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.03). Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The firm had revenue of $493.77 million during the quarter, compared to the consensus estimate of $486.23 million. During the same quarter in the prior year, the business posted $0.51 earnings per share. The firm’s quarterly revenue was down 1.7% on a year-over-year basis. Equities analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.